Caris Life Sciences, Inc.(CAI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAI Caris Life Sciences, Inc.

未开盘 09-30 16:00:00 EDT

30.63

-0.92

-2.92%

盘后30.91

+0.28+0.91%

19:51 EDT

最高32.04	最低30.60	成交量292.96万
今开31.40	昨收31.55	日振幅4.56%
总市值86.42亿	流通市值35.53亿	总股本2.82亿
成交额9,141万	换手率2.53%	流通股本1.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAI","market":"US","secType":"STK","nameCN":"Caris Life Sciences, Inc.","latestPrice":30.63,"timestamp":1790798400000,"preClose":31.55,"halted":0,"volume":2929550,"hourTrading":{"tag":"盘后","latestPrice":30.91,"preClose":30.63,"latestTime":"19:51 EDT","volume":83407,"amount":2554945.2565,"timestamp":1790812319404,"change":0.28,"changeRate":0.009141,"amplitude":0.010121},"delay":0,"changeRate":-0.02916006339144221,"floatShares":115999999,"shares":282146923,"eps":0.372,"marketStatus":"未开盘","change":-0.92,"latestTime":"09-30 16:00:00 EDT","open":31.4,"high":32.04,"low":30.6,"amount":91408463.601,"amplitude":0.045642,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.372,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1750219200000,"exchange":"NASDAQ","adjPreClose":31.55,"preHourTrading":{"tag":"盘前","latestPrice":31.99,"preClose":31.55,"latestTime":"09:10 EDT","volume":1944,"amount":61445.481552,"timestamp":1790773846511,"change":0.44,"changeRate":0.013946,"amplitude":0.046076},"postHourTrading":{"tag":"盘后","latestPrice":30.91,"preClose":30.63,"latestTime":"19:51 EDT","volume":83407,"amount":2554945.2565,"timestamp":1790812319404,"change":0.28,"changeRate":0.009141,"amplitude":0.010121},"volumeRatio":0.700385,"impliedVol":0.5179,"impliedVolPercentile":0.1076},"requestUrl":"/m/hq/s/CAI/tweets","defaultTab":"tweets","newsList":[{"id":"1112316493","title":"异动解读｜Caris Life Sciences盘中上涨5.38%，报32.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112316493","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112316493?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:11","pubTimestamp":1790086304,"startTime":"0","endTime":"0","summary":"9月22日，Caris Life Sciences盘中上涨5.38%，报32.28美元/股，成交额3335.41万美元。Caris Life Sciences所在的生物科技行业中，个股中，Viking Therapeutics涨33.38%，Moderna涨3.75%，Decoy Therapeutics涨158.98%，Greenland Mines涨36.2%，安进涨1.45%。Caris Life Sciences是一家以患者为中心的下一代AI科技生物公司和精准医疗先驱，致力于通过大规模使用综合分子信息和人工智能算法改变医疗保健，重点服务于肿瘤学领域的临床、学术和生物制药市场。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149868008","title":"异动解读｜Caris Life Sciences盘中上涨5.35%，业绩超预期叠加机构覆盖持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1149868008","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149868008?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:31","pubTimestamp":1789655473,"startTime":"0","endTime":"0","summary":"9月17日，Caris Life Sciences盘中上涨5.35%，报29.73美元/股，成交额2939.55万美元，延续近日强势表现。此外，公司二季度营收2.637亿美元，大幅超出市场预期的2.381亿美元；一季度营收同比增长79%，EPS实现盈亏平衡，均优于预期，全年营收指引10亿至10.2亿美元维持不变。产品端，公司接连推出PTEN IHC检测及ChromoSeq全基因组测序产品拓展精准肿瘤学版图，同时此前授权的1亿美元股票回购计划进一步增强市场信心，多重利好叠加持续推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"业绩超预期，Caris Life Sciences盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182041194","title":"异动解读｜Caris Life Sciences盘中上涨5.82%，瑞银首次覆盖叠加业绩强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1182041194","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182041194?lang=zh_cn&edition=full","pubTime":"2026-09-16 00:13","pubTimestamp":1789488807,"startTime":"0","endTime":"0","summary":"9月16日，Caris Life Sciences盘中上涨5.82%，报27.57美元/股，成交额8444.03万美元。消息面上，瑞银近日首次覆盖该股，给予中性评级及28美元目标价，分析师平均评级为\"超配\"，均值目标价27.08美元。此外，公司此前发布的二季度财报表现亮眼，营收2.637亿美元，大幅超出市场预期的2.381亿美元；一季度营收同比增长79%，EPS实现盈亏平衡，优于预期。产品端，公司持续推出PTEN IHC检测、ChromoSeq等新产品拓展精准肿瘤学版图，基本面多重利好叠加推动股价走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞银首予中性评级，Caris Life Sciences盘中上扬","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144814508","title":"异动解读｜Caris Life Sciences盘中下跌5.19%，报26.555美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144814508","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144814508?lang=zh_cn&edition=full","pubTime":"2026-08-26 23:27","pubTimestamp":1787758037,"startTime":"0","endTime":"0","summary":"8月26日，Caris Life Sciences盘中下跌5.19%，报26.555美元/股，成交额3942.12万美元。Caris Life Sciences所在的生物科技行业中，个股中，Moderna跌6.87%，安进跌0.46%，艾伯维公司跌1.66%，Revolution Medicines涨0.83%，吉利德科学跌0.15%。Caris Life Sciences, Inc.是一家领先的、以患者为中心的下一代AI科技生物公司和精准医疗先驱，致力于通过大规模使用综合分子信息和人工智能/机器学习算法来改变医疗保健，重点聚焦肿瘤学领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112064520","title":"异动解读｜Caris Life Sciences盘中上涨5.01%，报27.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112064520","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112064520?lang=zh_cn&edition=full","pubTime":"2026-08-26 00:21","pubTimestamp":1787674886,"startTime":"0","endTime":"0","summary":"8月25日，Caris Life Sciences盘中上涨5.01%，报27.44美元/股，成交额5724.56万美元。Caris Life Sciences所在的生物科技行业中，个股中，Moderna涨11.61%，Natera涨2.01%，安进涨0.24%，艾伯维公司涨0.69%，吉利德科学涨0.78%。Caris Life Sciences, Inc.是一家领先的、以患者为中心的下一代AI科技生物公司和精准医疗先驱，致力于通过大规模使用综合分子信息和人工智能/机器学习算法来改变医疗保健，重点聚焦肿瘤学领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159180465","title":"异动解读｜Caris Life Sciences盘中上涨5.09%，Q2业绩大超预期持续推动股价上行","url":"https://stock-news.laohu8.com/highlight/detail?id=1159180465","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159180465?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:33","pubTimestamp":1787322781,"startTime":"0","endTime":"0","summary":"8月21日，Caris Life Sciences盘中上涨5.09%，报25.85美元/股，成交额3132.56万美元，延续近期强势表现。消息面上，公司8月5日盘后发布的二季度财报显示，营收2.637亿美元，大幅超出市场一致预期的2.381亿美元，超预期幅度约10.7%。此外，公司近期在产品管线方面持续推进，包括推出PTEN IHC检测拓展转移性前列腺癌精准肿瘤学领域，以及向纽约州提交Caris Assure血液检测授权申请，基本面利好叠加推动市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Q2业绩大超预期，Caris Life Sciences盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159838381","title":"异动解读｜Caris Life Sciences盘中上涨7.89%，Q2业绩大超预期持续推动股价上行","url":"https://stock-news.laohu8.com/highlight/detail?id=1159838381","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159838381?lang=zh_cn&edition=full","pubTime":"2026-08-21 03:29","pubTimestamp":1787254174,"startTime":"0","endTime":"0","summary":"8月21日，Caris Life Sciences盘中上涨7.89%，报24.555美元/股，成交额1.0亿美元，延续近期强势表现。消息面上，公司8月5日盘后发布的二季度财报显示，营收2.637亿美元，大幅超出市场一致预期的2.381亿美元，超预期幅度约10.7%。此前一季度公司营收同比增长79%至2.162亿美元，全年营收指引维持10亿至10.2亿美元不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Caris Life Sciences大涨，Q2业绩超预期引爆行情","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122482270","title":"财报前瞻｜Caris Life Sciences, Inc.本季度营收预计增长74.08%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1122482270","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122482270?lang=zh_cn&edition=full","pubTime":"2026-07-29 12:31","pubTimestamp":1785299472,"startTime":"0","endTime":"0","summary":"Caris Life Sciences, Inc.将于2026年08月05日发布财报，市场预期公司本季度营收显著改善，盈利能力指标成关注焦点。- 由于未检索到本季度毛利率与净利润或净利率的明确预测数据，相关指标不予展示。多家机构近期对Caris Life Sciences, Inc.的观点偏正面，看多意见占比较高：主流观点认为本季度营收与EBIT的高增速预期建立在订单恢复和合作拓展的基础上，盈利的边际拐点值得跟踪；谨慎观点则提示回款与费用投入的不确定性仍存。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Caris Life Sciences, Inc.本季度营收预计增长74.08%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651910081","title":"Caris Life Sciences推出PTEN IHC检测拓展转移性前列腺癌精准肿瘤学","url":"https://stock-news.laohu8.com/highlight/detail?id=2651910081","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651910081?lang=zh_cn&edition=full","pubTime":"2026-07-14 23:59","pubTimestamp":1784044740,"startTime":"0","endTime":"0","summary":"Caris Life Sciences今日宣布，正式推出PTEN蛋白免疫组化检测服务，以进一步拓展其在转移性前列腺癌精准肿瘤学领域的解决方案。　　Caris Life Sciences是一家领先的分子科学和人工智能技术公司，致力于通过全面的分子谱分析赋能精准医疗。公司新推出的PTEN IHC检测，是一种基于组织的伴随诊断方法，用于评估前列腺癌患者肿瘤样本中PTEN蛋白的表达水平。　　Caris Life Sciences计划通过其专业的医学事务团队，为临床医生提供关于如何解读和应用PTEN IHC检测结果的教育和支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfz8058037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4162","IHC","PTEN","BK4092","BK4104","CANC","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641348011","title":"Caris Life Sciences授权1亿美元股票回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2641348011","media":"环球市场播报","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641348011?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:35","pubTimestamp":1780929300,"startTime":"0","endTime":"0","summary":"精准医疗公司Caris Life Sciences6月8日宣布，其董事会已授权一项最高达1亿美元的普通股回购计划。Caris计划以现有现金及现金等价物为此次回购提供资金支持。根据公司此前发布的第一季度财报，Caris在2026年第一季度实现总营收2.162亿美元，同比增长79%，其中分子分析服务收入增长85%至2.108亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-08/doc-iniathze8537387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4104","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101513685","title":"Caris Life Sciences 计划以可用现金及现金等价物为股票回购计划提供资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1101513685","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101513685?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:33","pubTimestamp":1780921985,"startTime":"0","endTime":"0","summary":"Caris Life Sciences 公司表示，其股票回购计划预计将完全通过现有的现金及现金等价物提供资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122496389","title":"Caris生命科学向纽约州卫生部提交Caris Assure血液检测授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1122496389","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122496389?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:08","pubTimestamp":1778270891,"startTime":"0","endTime":"0","summary":"Caris生命科学公司已正式向纽约州卫生部递交申请，旨在为其Caris Assure血液检测技术获取授权许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","CAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118576658","title":"Caris生命科学公司Caris Chromoseq获Moldx批准，推动髓系恶性肿瘤全面基因组图谱检测可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1118576658","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118576658?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:32","pubTimestamp":1777897936,"startTime":"0","endTime":"0","summary":"Caris生命科学公司宣布，其Caris Chromoseq检测技术已获得Moldx认证批准。这一重要进展将显著提升髓系恶性肿瘤患者获取全面基因组图谱检测服务的便利性。\n该项认证标志着Caris公司在精准医疗领域迈出关键一步。通过Moldx的权威认可，医疗机构和患者能够更便捷地运用这项先进技术，为髓系恶性肿瘤的精准诊断和治疗方案制定提供有力支持。\nCaris Chromoseq技术的推广应用，将助力临床医生基于个体基因特征制定个性化治疗方案，最终改善髓系恶性肿瘤患者的治疗效果和生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAI","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160274437","title":"财报前瞻｜Caris Life Sciences, Inc.本季度营收预计同比持平，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1160274437","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160274437?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:05","pubTimestamp":1777539947,"startTime":"0","endTime":"0","summary":"Caris Life Sciences, Inc.将于2026年05月07日盘后发布财报，市场预期本季度营收约2.10亿美元、调整后每股收益约-0.02美元。市场一致预期显示，Caris Life Sciences, Inc.本季度营收预计为2.10亿美元，调整后每股收益预计为-0.02美元；公司层面未给出本季度毛利率与净利润或净利率的量化指引，相关预测数据暂无。公司近期在检测项目上持续扩充：推出用于预测高级别浆液性卵巢癌对铂类化疗耐受风险的AI工具，嵌入Caris AI Insights平台，为临床医生提供风险评分与敏感性预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Caris Life Sciences, Inc.本季度营收预计同比持平，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628273004","title":"华安保险：李云焕因个人原因辞去公司总经理职务 指定CAI ZHENGYUAN为临时负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2628273004","media":"金融一线","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628273004?lang=zh_cn&edition=full","pubTime":"2026-04-17 15:16","pubTimestamp":1776410160,"startTime":"0","endTime":"0","summary":"4月17日金融一线消息，华安财产保险股份有限公司近日公告称，李云焕因个人原因辞去公司总经理职务，根据公司第九届董事会第十次临时会议决议，董事会指定 CAI ZHENGYUAN先生为公司临时负责人，指定期不超过六个月。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王馨茹","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/2026-04-17/doc-inhuutza2283707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CAI","BK4104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146321171","title":"Caris生命科学公司与Blue Owl Capital及黑石集团达成新信贷协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1146321171","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146321171?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:30","pubTimestamp":1775161821,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Caris生命科学公司（Caris Life Sciences, Inc.）已与Blue Owl Capital及黑石集团（Blackstone）正式签署了一项新的信贷协议。\n该协议的达成标志着Caris生命科学公司在资本结构优化方面迈出关键一步，为其未来的研发投入与业务扩张提供了坚实的资金支持。此次合作也凸显了Blue Owl Capital与黑石集团对生命科学领域创新企业的持续看好。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149391494","title":"Caris生命科学公司信贷协议披露：4亿美元定期贷款、3亿美元延迟提款及5亿美元增量融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1149391494","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149391494?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:30","pubTimestamp":1775161820,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会（SEC）文件，Caris生命科学公司（Caris Life Sciences Inc）已达成一项综合性信贷协议。该协议包含三部分核心融资安排：一项4亿美元的定期贷款、一项3亿美元的延迟提款贷款，以及一项高达5亿美元的增量融资额度。\n此项信贷安排显著增强了公司的财务灵活性。定期贷款提供即时资金支持，延迟提款机制允许公司根据未来需求分阶段获取资金，而增量融资额度则为潜在的战略扩张预留了充足空间。\n这一融资动作为Caris生命科学后续的研发投入与业务拓展提供了坚实的资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carislifesciences.com","stockEarnings":[{"period":"1week","weight":-0.0322},{"period":"1month","weight":0.2016},{"period":"3month","weight":0.6738},{"period":"6month","weight":0.5879},{"period":"1year","weight":0.0126},{"period":"ytd","weight":0.1353}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Caris Life Sciences, Inc.于2011年11月根据开曼群岛法律注册成立，并于2020年7月在德克萨斯州重新注册成立，总部位于德克萨斯州欧文。他们是一家领先的、以患者为中心的下一代AI科技生物公司和精准医疗先驱。他们开发并商业化创新解决方案，通过大规模使用综合分子信息和人工智能/机器学习算法来改变医疗保健。他们的整个精准医疗解决方案组合旨在造福患者，最初的重点是肿瘤学，并服务于临床、学术和生物制药市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":0.003709},{"month":2,"riseRate":0.714286,"avgChangeRate":0.097096},{"month":3,"riseRate":0.785714,"avgChangeRate":0.045627},{"month":4,"riseRate":0.642857,"avgChangeRate":0.069907},{"month":5,"riseRate":0.571429,"avgChangeRate":0.009049},{"month":6,"riseRate":0.4,"avgChangeRate":0.003897},{"month":7,"riseRate":0.533333,"avgChangeRate":0.001503},{"month":8,"riseRate":0.466667,"avgChangeRate":0.000804},{"month":9,"riseRate":0.533333,"avgChangeRate":-0.003567},{"month":10,"riseRate":0.666667,"avgChangeRate":0.042552},{"month":11,"riseRate":0.533333,"avgChangeRate":0.007248},{"month":12,"riseRate":0.4,"avgChangeRate":-0.027079}],"exchange":"NASDAQ","name":"Caris Life Sciences, Inc.","nameEN":"Caris Life Sciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Caris Life Sciences, Inc.(CAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Caris Life Sciences, Inc.(CAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Caris Life Sciences, Inc.,CAI,Caris Life Sciences, Inc.股票,Caris Life Sciences, Inc.股票老虎,Caris Life Sciences, Inc.股票老虎国际,Caris Life Sciences, Inc.行情,Caris Life Sciences, Inc.股票行情,Caris Life Sciences, Inc.股价,Caris Life Sciences, Inc.股市,Caris Life Sciences, Inc.股票价格,Caris Life Sciences, Inc.股票交易,Caris Life Sciences, Inc.股票购买,Caris Life Sciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Caris Life Sciences, Inc.(CAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Caris Life Sciences, Inc.(CAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}